Stockholm - Delayed Quote SEK

Diagonal Bio AB (publ) (DIABIO.ST)

0.0145
0.0000
(0.00%)
At close: March 18 at 5:09:21 PM GMT+1
Loading Chart for DIABIO.ST
  • Previous Close 0.0145
  • Open 0.0148
  • Bid 0.0138 x --
  • Ask 0.0142 x --
  • Day's Range 0.0145 - 0.0145
  • 52 Week Range 0.0120 - 0.0170
  • Volume 4,667,208
  • Avg. Volume 6,225,678
  • Market Cap (intraday) 17.617M
  • Beta (5Y Monthly) -1.83
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Diagonal Bio AB (publ) operates as a biotechnology company in Sweden. The company offers LAMPlify, a customized system for general laboratory use to identify the presence of specific genetic markers for, for example, fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid and accurate point-of-care diagnoses in various settings, such as doctor's office, surgery, mobile clinics, hospital bedsides, and workplaces and airports. The company was incorporated in 2020 and is based in Lund, Sweden.

diagonalbio.com

4

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DIABIO.ST

View More

Performance Overview: DIABIO.ST

Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

DIABIO.ST
3.33%
OMX Stockholm 30 Index (^OMX)
1.84%

1-Year Return

DIABIO.ST
3.33%
OMX Stockholm 30 Index (^OMX)
3.66%

3-Year Return

DIABIO.ST
3.33%
OMX Stockholm 30 Index (^OMX)
25.72%

5-Year Return

DIABIO.ST
3.33%
OMX Stockholm 30 Index (^OMX)
66.07%

Compare To: DIABIO.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DIABIO.ST

View More

Valuation Measures

As of 5/12/2025
  • Market Cap

    15.79M

  • Enterprise Value

    14.06M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    99.64

  • Price/Book (mrq)

    0.59

  • Enterprise Value/Revenue

    611.50

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -21.17%

  • Return on Equity (ttm)

    -43.32%

  • Revenue (ttm)

    1.12M

  • Net Income Avi to Common (ttm)

    -9.93M

  • Diluted EPS (ttm)

    -0.3000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    818k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -9.99M

Research Analysis: DIABIO.ST

View More

People Also Watch